Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study

Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (N...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 1; p. e54163
Main Authors Hoffer, Michael E., Balaban, Carey, Slade, Martin D., Tsao, Jack W., Hoffer, Barry
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 23.01.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0054163

Cover

Abstract Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted. ClinicalTrials.gov NCT00822263.
AbstractList Background Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. Methods This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. Conclusion This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted. Trial Registration ClinicalTrials.gov NCT00822263
Background Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. Methods This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of ‘no day 7 symptoms’ indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. Conclusion This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted. Trial Registration ClinicalTrials.gov NCT00822263
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted.
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting.This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo.This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted.ClinicalTrials.gov NCT00822263.
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting.BACKGROUNDMild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting.This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo.METHODSThis study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo.This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted.CONCLUSIONThis study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted.ClinicalTrials.gov NCT00822263.TRIAL REGISTRATIONClinicalTrials.gov NCT00822263.
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted. ClinicalTrials.gov NCT00822263.
Audience Academic
Author Slade, Martin D.
Tsao, Jack W.
Balaban, Carey
Hoffer, Michael E.
Hoffer, Barry
AuthorAffiliation 2 Departments of Otolaryngology, Neurobiology, Communication Sciences and Disorders, and Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
University of Toronto, Canada
1 Spatial Orientation Center, Department of Otolaryngology, Naval Medical Center San Diego, San Diego, California, United States of America
4 Wounded, Ill and Injured Directorate (M9), US Navy Bureau of Medicine and Surgery, Washington, D.C., United States of America
3 Department of Internal Medicine, Yale University, New Haven, Connecticut, United States of America
5 Department of Neurosurgery, Case Western University, Cleveland, Ohio, United States of America
AuthorAffiliation_xml – name: 2 Departments of Otolaryngology, Neurobiology, Communication Sciences and Disorders, and Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
– name: 5 Department of Neurosurgery, Case Western University, Cleveland, Ohio, United States of America
– name: University of Toronto, Canada
– name: 3 Department of Internal Medicine, Yale University, New Haven, Connecticut, United States of America
– name: 1 Spatial Orientation Center, Department of Otolaryngology, Naval Medical Center San Diego, San Diego, California, United States of America
– name: 4 Wounded, Ill and Injured Directorate (M9), US Navy Bureau of Medicine and Surgery, Washington, D.C., United States of America
Author_xml – sequence: 1
  givenname: Michael E.
  surname: Hoffer
  fullname: Hoffer, Michael E.
– sequence: 2
  givenname: Carey
  surname: Balaban
  fullname: Balaban, Carey
– sequence: 3
  givenname: Martin D.
  surname: Slade
  fullname: Slade, Martin D.
– sequence: 4
  givenname: Jack W.
  surname: Tsao
  fullname: Tsao, Jack W.
– sequence: 5
  givenname: Barry
  surname: Hoffer
  fullname: Hoffer, Barry
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23372680$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tu1DAQhiNURA_wBggsVUIgsYsdJ3bSC6TtclqpUEQLt5bjTLZeeeNiJ4h9BZ6a2UOr3apCKBeJZ77_d2bsOUz2Wt9CkjxldMi4ZG9mvg-tdsNrDA8pzTMm-IPkgJU8HYiU8r2t7_3kMMYZQrwQ4lGyn3IuU1HQg-TPaA7O-qA761viGzIyfQfkAn724DQsI6dOx45M2ro3UJPP1tXkMuh-jhJDToO2LSZnfViQakG-DEYGuoUj40XswLZwQkbkne8rB4NTZ9v6NfnqtIHKk7Fvu-CdQ9OLrq8Xj5OHjXYRnmzeR8n3D-8vx58GZ-cfJ-PR2cAIKvlAm6o0kBaQGk5NXhhNS6FTQ2mRmZzVVY0LJrMGMiqqholSYpqXjUFSyJwfJc_XvtfOR7VpY1SMp1KWZVYuicmaqL2eqetg5zoslNdWrQI-TJUOWL0Dlaaa5rqgrKhFxqqipE2ZiRoqmZtUS41ebze79dUcagNYtHY7pruZ1l6pqf-leJ5zJhgavNwYBI-HEjs1t9GAc7oF3-N_pwUepsxyiujxHfT-6jbUVGMBtm087muWpmqUyYJlhVxRw3sofGqYW4N3rrEY3xG82hEg08Hvbqr7GNXk4tv_s-c_dtkXW-wVaNddRe_65YWNu-Cz7U7ftvjmsiOQrQETfIwBmluEUbWcqZt2qeVMqc1MoezkjszYbjUv2BHr_i3-C30CJt8
CitedBy_id crossref_primary_10_2147_NDT_S241497
crossref_primary_10_1016_j_phrs_2022_106550
crossref_primary_10_1038_s41598_017_04941_w
crossref_primary_10_1089_neu_2014_3855
crossref_primary_10_1517_13543784_2015_960076
crossref_primary_10_1016_j_brainres_2016_02_006
crossref_primary_10_1016_j_brainres_2016_02_007
crossref_primary_10_3389_fncel_2020_00218
crossref_primary_10_1016_j_neubiorev_2017_11_011
crossref_primary_10_1080_02699052_2017_1288928
crossref_primary_10_1097_HTR_0000000000000976
crossref_primary_10_1007_s00415_022_11240_6
crossref_primary_10_1016_j_jconrel_2023_01_065
crossref_primary_10_3390_antiox13030303
crossref_primary_10_1038_s41582_019_0243_8
crossref_primary_10_3389_fneur_2017_00219
crossref_primary_10_1002_ar_24066
crossref_primary_10_1016_j_jalz_2015_07_489
crossref_primary_10_1002_lio2_89
crossref_primary_10_1016_j_neuchi_2021_02_001
crossref_primary_10_1016_j_expneurol_2020_113307
crossref_primary_10_1016_j_jneumeth_2016_04_021
crossref_primary_10_3928_00485713_20130703_06
crossref_primary_10_1016_j_expneurol_2014_07_013
crossref_primary_10_1089_neu_2019_6591
crossref_primary_10_1371_journal_pone_0080138
crossref_primary_10_1016_j_pnpbp_2017_04_021
crossref_primary_10_1371_journal_pone_0113264
crossref_primary_10_3138_jmvfh_2022_0084
crossref_primary_10_1371_journal_pone_0090617
crossref_primary_10_1016_j_brainres_2021_147541
crossref_primary_10_3233_JAD_160241
crossref_primary_10_3390_ijerph17072585
crossref_primary_10_1016_j_jneumeth_2016_02_002
crossref_primary_10_1016_j_jneumeth_2016_02_001
crossref_primary_10_1016_j_pmrj_2015_02_002
crossref_primary_10_1089_neur_2023_0124
crossref_primary_10_1007_s40263_022_00907_3
crossref_primary_10_1007_s12035_018_1011_2
crossref_primary_10_1186_s13287_019_1436_1
crossref_primary_10_1097_JSM_0000000000000195
crossref_primary_10_1155_2022_3999083
crossref_primary_10_1172_jci_insight_149229
crossref_primary_10_1016_j_expneurol_2014_04_020
crossref_primary_10_1080_00498254_2016_1187777
crossref_primary_10_1186_s12987_017_0061_6
crossref_primary_10_1016_j_neuint_2019_104605
crossref_primary_10_3390_nu16152430
crossref_primary_10_1016_j_neuint_2021_105192
crossref_primary_10_1124_mol_117_109926
crossref_primary_10_1016_j_cct_2023_107250
crossref_primary_10_1016_j_taap_2016_02_010
crossref_primary_10_1007_s00213_017_4762_y
crossref_primary_10_1016_S1474_4422_13_70161_3
crossref_primary_10_3390_antibiotics12040740
crossref_primary_10_1016_j_apmr_2014_10_026
crossref_primary_10_3389_fnut_2022_977728
crossref_primary_10_1097_WCO_0000000000000164
crossref_primary_10_3389_fneur_2024_1282198
crossref_primary_10_1016_j_neuroscience_2013_09_049
crossref_primary_10_1016_j_expneurol_2015_05_024
crossref_primary_10_1089_neu_2018_6203
crossref_primary_10_1186_s12916_016_0560_3
crossref_primary_10_1111_wvn_12167
crossref_primary_10_4085_1062_6050_142_19
crossref_primary_10_1007_s40263_016_0355_2
crossref_primary_10_3390_biomedicines12040781
crossref_primary_10_1371_journal_pone_0157064
crossref_primary_10_1371_journal_pone_0156493
crossref_primary_10_1249_JSR_0000000000000752
crossref_primary_10_1016_j_ncl_2015_04_004
crossref_primary_10_1016_j_neuchi_2020_09_001
crossref_primary_10_1097_JSM_0000000000000412
crossref_primary_10_3389_fnsys_2016_00008
crossref_primary_10_3389_fneur_2017_00744
crossref_primary_10_1016_j_neurot_2024_e00515
crossref_primary_10_1016_j_jalz_2013_12_011
crossref_primary_10_3389_fcell_2020_00594
crossref_primary_10_1002_hipo_22580
crossref_primary_10_1089_neu_2015_4113
crossref_primary_10_1016_j_neubiorev_2015_04_015
crossref_primary_10_1111_fcp_12767
crossref_primary_10_3389_fnins_2021_635483
crossref_primary_10_1002_jnr_24132
crossref_primary_10_1016_j_jocrd_2020_100529
crossref_primary_10_1016_j_neuint_2017_07_014
crossref_primary_10_1016_j_smrv_2022_101631
crossref_primary_10_4103_aihb_aihb_10_25
crossref_primary_10_31083_JIN25292
crossref_primary_10_26644_em_2019_001
crossref_primary_10_1093_cercor_bhw318
crossref_primary_10_1177_0194599813515184
crossref_primary_10_1249_JSR_0000000000000387
crossref_primary_10_15406_jnsk_2015_02_00041
crossref_primary_10_1016_j_otc_2022_06_006
crossref_primary_10_1089_neu_2013_3019
crossref_primary_10_1016_j_expneurol_2020_113507
crossref_primary_10_1089_neu_2015_4350
crossref_primary_10_1186_s13063_016_1529_4
crossref_primary_10_1371_journal_pone_0180280
crossref_primary_10_1080_13543784_2017_1269171
crossref_primary_10_3390_antiox9040297
crossref_primary_10_1016_j_isci_2020_101628
crossref_primary_10_3390_ijms221910555
crossref_primary_10_3390_ijms25084146
crossref_primary_10_1249_JSR_0000000000000132
crossref_primary_10_2174_1874467214666210203211914
crossref_primary_10_25259_SNI_773_2023
crossref_primary_10_3390_ijms23169328
crossref_primary_10_1007_s13311_023_01422_z
crossref_primary_10_1002_acn3_51325
crossref_primary_10_3390_antiox9030260
crossref_primary_10_1186_s40035_017_0088_2
crossref_primary_10_1080_02699052_2024_2396017
crossref_primary_10_1016_j_neuint_2024_105874
crossref_primary_10_3389_fneur_2020_00438
crossref_primary_10_1001_jamaneurol_2020_5079
crossref_primary_10_4103_1673_5374_165309
crossref_primary_10_1007_s10571_014_0069_2
crossref_primary_10_1016_j_earlhumdev_2019_03_006
crossref_primary_10_1111_ene_13971
crossref_primary_10_1155_2020_8837893
crossref_primary_10_1016_j_neulet_2013_12_023
crossref_primary_10_1017_S0033291716002932
crossref_primary_10_1097_JSM_0000000000000745
crossref_primary_10_1002_npr2_12360
crossref_primary_10_1080_10715762_2025_2450504
crossref_primary_10_3389_fneur_2019_00650
crossref_primary_10_3390_molecules23020245
crossref_primary_10_3928_00485713_20170103_02
crossref_primary_10_1016_j_expneurol_2013_09_002
crossref_primary_10_1097_TA_0000000000003639
crossref_primary_10_1089_neu_2015_4342
crossref_primary_10_1186_s12929_017_0377_1
crossref_primary_10_1016_j_csm_2020_08_015
crossref_primary_10_1111_cns_13300
crossref_primary_10_1111_dar_12414
crossref_primary_10_1155_2022_1274550
crossref_primary_10_1089_neu_2017_5348
crossref_primary_10_1249_JSR_0000000000000557
crossref_primary_10_1016_j_freeradbiomed_2018_06_031
crossref_primary_10_3390_medicines11050010
crossref_primary_10_1016_j_tins_2016_03_002
Cites_doi 10.3109/00016489309135768
10.1682/JRRD.2007.09.0140
10.1093/acprof:oso/9780195328318.003.0012
10.2174/092986709789878292
10.1080/00016480601110188
10.1016/0197-2456(90)90005-M
10.1097/MAO.0b013e3181c993c3
10.1001/jama.2012.13444
10.1016/S0928-4680(01)00067-0
10.1016/j.heares.2006.10.008
10.1002/jnr.21160
10.2522/ptj.20070130
10.1056/NEJMe078235
10.2174/0929867033456567
10.1089/089771502320317131
10.1016/j.expneurol.2011.09.018
10.1089/089771503767870014
10.1016/S0891-5849(97)00137-8
10.1038/nn.2250
10.1124/pr.54.2.271
10.1002/jnr.20087
10.1016/j.neuroscience.2003.12.040
10.1097/MAO.0b013e31822e5bee
10.1093/arclin/11.4.329
10.1089/neu.2008.0602
10.1097/HTR.0b013e31819581d8
10.1093/ptj/84.2.151
10.7205/MILMED.172.7.726
10.1016/S0887-6177(03)00039-8
10.1017/S0022215100128555
10.1038/sj.bjp.0703421
10.1093/arclin/acr024
10.1007/s11064-006-9040-z
10.1056/NEJMoa072972
10.1097/TA.0b013e318160773e
10.1016/S0006-8993(03)02244-3
10.1002/msj.20098
ContentType Journal Article
Copyright COPYRIGHT 2013 Public Library of Science
2013. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2013
Copyright_xml – notice: COPYRIGHT 2013 Public Library of Science
– notice: 2013. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2013
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0054163
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Opposing Viewpoints in Context
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (ProQuest)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agriculture Science Database
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database (ProQuest)
Engineering Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



Agricultural Science Database


MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Medicine
Biology
DocumentTitleAlternate Amelioration of Sequelae of Blast mTBI by NAC
EISSN 1932-6203
ExternalDocumentID 1327799495
oai_doaj_org_article_22a05a8018d641b890f946deb75c2a7a
PMC3553161
2946373601
A478148795
23372680
10_1371_journal_pone_0054163
Genre Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESTFP
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPNFZ
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PUEGO
PYCSY
RIG
RNS
RPM
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
PV9
RZL
BBORY
PMFND
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
AAPBV
ABPTK
BBAFP
N95
ID FETCH-LOGICAL-c6073-acb9ce28e2c30c58ca096a2c0084c51dbda2c174fe406bf16976a239fcca06753
IEDL.DBID M48
ISSN 1932-6203
IngestDate Sun Nov 06 00:11:18 EDT 2022
Wed Aug 27 01:31:53 EDT 2025
Tue Sep 30 16:58:38 EDT 2025
Fri Sep 05 05:31:49 EDT 2025
Fri Jul 25 10:35:30 EDT 2025
Tue Jun 17 21:42:13 EDT 2025
Tue Jun 10 20:50:18 EDT 2025
Fri Jun 27 03:33:14 EDT 2025
Fri Jun 27 05:06:07 EDT 2025
Thu May 22 21:17:34 EDT 2025
Mon Jul 21 06:00:49 EDT 2025
Thu Apr 24 23:13:02 EDT 2025
Wed Oct 01 03:04:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Creative Commons CC0 public domain
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c6073-acb9ce28e2c30c58ca096a2c0084c51dbda2c174fe406bf16976a239fcca06753
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
Conceived and designed the experiments: MEH CB. Performed the experiments: MEH. Analyzed the data: CB MS JT BH. Contributed reagents/materials/analysis tools: CB JT. Wrote the paper: MEH CB MS JT BH.
Competing Interests: The authors have declared that no competing interests exist.
OpenAccessLink https://www.proquest.com/docview/1327799495?pq-origsite=%requestingapplication%
PMID 23372680
PQID 1327799495
PQPubID 1436336
PageCount e54163
ParticipantIDs plos_journals_1327799495
doaj_primary_oai_doaj_org_article_22a05a8018d641b890f946deb75c2a7a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3553161
proquest_miscellaneous_1283727450
proquest_journals_1327799495
gale_infotracmisc_A478148795
gale_infotracacademiconefile_A478148795
gale_incontextgauss_ISR_A478148795
gale_incontextgauss_IOV_A478148795
gale_healthsolutions_A478148795
pubmed_primary_23372680
crossref_primary_10_1371_journal_pone_0054163
crossref_citationtrail_10_1371_journal_pone_0054163
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20130123
PublicationDateYYYYMMDD 2013-01-23
PublicationDate_xml – month: 1
  year: 2013
  text: 20130123
  day: 23
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2013
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References CW Hoge (ref4) 2008; 358
RJN Garth (ref30) 1994; 108
S Wagner (ref25) 2011; 26
KM Cave (ref29) 2007; 172
A Saljo (ref38) 2003; 20
K Pahan (ref14) 1998; 24
TV Pereira (ref45) 2012; 308
WD Dupont (ref27) 1990; 11
ME Hoffer (ref35) 2010; 31
H Terrio (ref1) 2009; 24
AE Ritenour (ref32) 2008; 64
T Hicdonmez (ref9) 2006; 31
Y Gilgun-Sherki (ref13) 2002; 54
AM Stranahan (ref44) 2009; 16
D Tweedie (ref46) 2007; 85
AM Hart (ref10) 2004; 125
M Khan (ref7) 2004; 76
HL Lew (ref31) 2007; 44
ref24
ref23
EC Bielefeld (ref11) 2007; 127
F Santangelo (ref15) 2003; 10
JH Jensen (ref34) 1993; 113
K Moussawi (ref16) 2009; 12
ref20
ref41
Y Agrawal (ref18) 2011; 32
ref22
V Rubovitch (ref42) 2011; 232
GA Elder (ref2) 2009; 76
RA Bryant (ref3) 2008; 358
RM Ruff (ref21) 1996; 11
A Saljo (ref39) 2002; 19
MC Schubert (ref17) 2004; 84
A Saljo (ref37) 2001; 8
ref28
S Cuzzocrea (ref6) 2000; 130
B Sekhon (ref8) 2003; 971
S-Y Tsai (ref36) 2009
TN Tombaugh (ref26) 2004; 19
ref5
H De Vries (ref43) 1996; 49
GF Marchetti (ref19) 2008; 88
RD Kopke (ref12) 2007; 226
DJ James (ref33) 1982; No. 04/82
A Saljo (ref40) 2008; 25
19158592 - J Head Trauma Rehabil. 2009 Jan-Feb;24(1):14-23
21576092 - Arch Clin Neuropsychol. 2011 Jun;26(4):314-21
14588937 - Arch Clin Neuropsychol. 1996;11(4):329-38
8442424 - Acta Otolaryngol. 1993 Jan;113(1):62-7
12965057 - J Neurotrauma. 2003 Aug;20(8):787-94
15010086 - Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
16758355 - Neurochem Res. 2006 Apr;31(4):473-81
17691685 - Mil Med. 2007 Jul;172(7):726-30
12037143 - Pharmacol Rev. 2002 Jun;54(2):271-84
18292216 - Phys Ther. 2008 May;88(5):640-51
14529474 - Curr Med Chem. 2003 Dec;10(23):2599-610
17712668 - Acta Otolaryngol. 2007 Sep;127(9):914-9
9228664 - Pharmacol Rev. 1997 Jun;49(2):143-55
12225658 - J Neurotrauma. 2002 Aug;19(8):985-91
20009782 - Otol Neurotol. 2010 Feb;31(2):232-6
10903958 - Br J Pharmacol. 2000 Jul;130(6):1219-26
18234757 - N Engl J Med. 2008 Jan 31;358(5):525-7
23093165 - JAMA. 2012 Oct 24;308(16):1676-84
17184943 - Hear Res. 2007 Apr;226(1-2):114-25
18376162 - J Trauma. 2008 Feb;64(2 Suppl):S174-8; discussion S178
21892121 - Otol Neurotol. 2011 Oct;32(8):1309-11
12691831 - Brain Res. 2003 May 2;971(1):1-8
14744205 - Phys Ther. 2004 Feb;84(2):151-8
2161310 - Control Clin Trials. 1990 Apr;11(2):116-28
19136971 - Nat Neurosci. 2009 Feb;12(2):182-9
11720806 - Pathophysiology. 2001 Dec;8(2):105-111
21946269 - Exp Neurol. 2011 Dec;232(2):280-9
20018732 - Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22468-73
19903142 - Curr Med Chem. 2009;16(35):4668-78
19146459 - J Neurotrauma. 2008 Dec;25(12):1397-406
15051148 - Neuroscience. 2004;125(1):91-101
18234750 - N Engl J Med. 2008 Jan 31;358(5):453-63
7829942 - J Laryngol Otol. 1994 Nov;108(11):925-9
9436612 - Free Radic Biol Med. 1998 Jan 1;24(1):39-48
18075949 - J Rehabil Res Dev. 2007;44(7):921-8
19306373 - Mt Sinai J Med. 2009 Apr;76(2):111-8
15114624 - J Neurosci Res. 2004 May 15;76(4):519-27
17243171 - J Neurosci Res. 2007 Mar;85(4):805-15
References_xml – volume: 113
  start-page: 62
  year: 1993
  ident: ref34
  article-title: Experimental pressure induced rupture of the tympanic membrane in man
  publication-title: Acta Otolaryngol
  doi: 10.3109/00016489309135768
– volume: 44
  start-page: 921
  year: 2007
  ident: ref31
  article-title: Auditory dysfunction in traumatic brain injury
  publication-title: J Rehab Research, Development
  doi: 10.1682/JRRD.2007.09.0140
– ident: ref28
  doi: 10.1093/acprof:oso/9780195328318.003.0012
– volume: 16
  start-page: 4668
  year: 2009
  ident: ref44
  article-title: Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective efforts
  publication-title: Current Medicinal Chemistry
  doi: 10.2174/092986709789878292
– ident: ref5
– ident: ref20
– volume: 49
  start-page: 143
  year: 1996
  ident: ref43
  article-title: The blood-brain barrier in neuroinflammatory diseases
  publication-title: Pharmacological Reviews
– volume: 127
  start-page: 914
  year: 2007
  ident: ref11
  article-title: Noise protection with N-acetyl-l-cysteine (NAC) using a variety of noise exposures, NAC doses, and routes of administration
  publication-title: Acta Otolaryngol
  doi: 10.1080/00016480601110188
– volume: 11
  start-page: 116
  year: 1990
  ident: ref27
  article-title: Power and sample size calculations: a review and computer program
  publication-title: Controlled Clinical Trials
  doi: 10.1016/0197-2456(90)90005-M
– volume: 31
  start-page: 232
  year: 2010
  ident: ref35
  article-title: Blast exposure: vestibular consequences and associated characteristics
  publication-title: Otology & Neurotology
  doi: 10.1097/MAO.0b013e3181c993c3
– ident: ref41
– volume: 308
  start-page: 1676
  year: 2012
  ident: ref45
  article-title: Empirical evaluation of very large treatment effects of medical interventions
  publication-title: JAMA
  doi: 10.1001/jama.2012.13444
– volume: 8
  start-page: 105
  year: 2001
  ident: ref37
  article-title: Exposure to short-lasting impulse noise causes microglial and astroglial cell activation in the adult rat brain
  publication-title: Pathophysiology
  doi: 10.1016/S0928-4680(01)00067-0
– ident: ref24
– volume: 226
  start-page: 114
  year: 2007
  ident: ref12
  article-title: NAC for noise: from the bench top to the clinic
  publication-title: Hearing Research
  doi: 10.1016/j.heares.2006.10.008
– ident: ref22
– volume: 85
  start-page: 805
  year: 2007
  ident: ref46
  article-title: Apoptotic and behavioral sequelae of mild brain trauma in mice
  publication-title: J Neurosci Res
  doi: 10.1002/jnr.21160
– volume: 88
  start-page: 640
  year: 2008
  ident: ref19
  article-title: Temporal and spatial characteristics of gait during performance of the Dynamic Gait Index in people with and people without balance or vestibular disorders
  publication-title: Phys Ther
  doi: 10.2522/ptj.20070130
– volume: 358
  start-page: 525
  year: 2008
  ident: ref3
  article-title: Disentangling mild traumatic brain injury and stress reactions
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJMe078235
– volume: 10
  start-page: 2599
  year: 2003
  ident: ref15
  article-title: Intracellular thiol concentration modulating inflammatory response: influence on the regulation of cell functions through cysteine prodrug approach
  publication-title: Current Medicinal Chemistry
  doi: 10.2174/0929867033456567
– volume: 19
  start-page: 985
  year: 2002
  ident: ref39
  article-title: Exposure to short-lasting impulse noise causes neuronal c-Jun expression and induction of apoptosis in the adult rat brain
  publication-title: J Neurotrauma
  doi: 10.1089/089771502320317131
– volume: 232
  start-page: 280
  year: 2011
  ident: ref42
  article-title: A mouse model of blast-induced mild traumatic brain injury
  publication-title: Exp Neurol
  doi: 10.1016/j.expneurol.2011.09.018
– year: 2009
  ident: ref36
  article-title: Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving
  publication-title: Rac1·GTP pathway PNAS
– volume: 20
  start-page: 787
  year: 2003
  ident: ref38
  article-title: Impulse noise transiently increased the permeability of nerve and glial cell membranes, an effect accentuated by a recent brain injury
  publication-title: J Neurotrauma
  doi: 10.1089/089771503767870014
– volume: 24
  start-page: 39
  year: 1998
  ident: ref14
  article-title: N-acetyl cysteine inhibits induction of NO production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes
  publication-title: Free Radical Biology & Medicine
  doi: 10.1016/S0891-5849(97)00137-8
– volume: 12
  start-page: 182
  year: 2009
  ident: ref16
  article-title: N-Acetylcysteine reverses cocaine-induced metaplasticity
  publication-title: Nature Neuroscience
  doi: 10.1038/nn.2250
– volume: 54
  start-page: 271
  year: 2002
  ident: ref13
  article-title: Antioxidant therapy in acute central nervous system injury: current state
  publication-title: Pharmacological Reviews
  doi: 10.1124/pr.54.2.271
– volume: 76
  start-page: 519
  year: 2004
  ident: ref7
  article-title: Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke
  publication-title: Journal of Neuroscience Research
  doi: 10.1002/jnr.20087
– volume: 125
  start-page: 91
  year: 2004
  ident: ref10
  article-title: Sensory neuroprotection, mitochondrial preservation, and therapeutic potential of N-acetyl-cysteine after nerve injury
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2003.12.040
– volume: 32
  start-page: 309
  year: 2011
  ident: ref18
  article-title: The modified Romberg Balance Test: normative data in U.S. adults
  publication-title: Otol Neurotol
  doi: 10.1097/MAO.0b013e31822e5bee
– volume: No. 04/82
  year: 1982
  ident: ref33
  article-title: The response of the human ear to blast. Part 1: The effect on the ear drum of a short duration, fast rising pressure wave
  publication-title: Army Weapons Research Establishment/Chemical Defense Establishment Report
– volume: 11
  start-page: 329
  year: 1996
  ident: ref21
  article-title: Benton Controlled Oral Word Association Test: reliability and updated norms
  publication-title: Clinical Neuropsychol
  doi: 10.1093/arclin/11.4.329
– volume: 25
  start-page: 1397
  year: 2008
  ident: ref40
  article-title: Neuropathology and pressure in the pig brain resulting from low-impulse noise exposure
  publication-title: J Neurotrauma
  doi: 10.1089/neu.2008.0602
– volume: 24
  start-page: 14
  year: 2009
  ident: ref1
  article-title: Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team
  publication-title: J Head Trauma Rehabil
  doi: 10.1097/HTR.0b013e31819581d8
– volume: 84
  start-page: 151
  year: 2004
  ident: ref17
  article-title: Optimizing the sensitivity of the head thrust test for identifying vestibular hypofunction
  publication-title: Phys Ther
  doi: 10.1093/ptj/84.2.151
– volume: 172
  start-page: 726
  year: 2007
  ident: ref29
  article-title: Blast injury of the ear: clinical update from the global war on terror
  publication-title: Military Medicine
  doi: 10.7205/MILMED.172.7.726
– volume: 19
  start-page: 203
  year: 2004
  ident: ref26
  article-title: Trail Making Test A and B: Normative data stratified by age and education
  publication-title: Archives of Clinical Neuropsychology
  doi: 10.1016/S0887-6177(03)00039-8
– volume: 108
  start-page: 925
  year: 1994
  ident: ref30
  article-title: Blast injury of the auditory system: a review of mechanisms and pathology
  publication-title: J Laryngol Otol
  doi: 10.1017/S0022215100128555
– volume: 130
  start-page: 1219
  year: 2000
  ident: ref6
  article-title: Beneficial effects of n-acetylcysteine on ischaemic brain injury
  publication-title: British Journal of Pharmacology
  doi: 10.1038/sj.bjp.0703421
– volume: 26
  start-page: 314
  year: 2011
  ident: ref25
  article-title: Reliability of three alternate forms of theTrail Making Tests A and B
  publication-title: Archives of Clinical Neuropsychology
  doi: 10.1093/arclin/acr024
– volume: 31
  start-page: 473
  year: 2006
  ident: ref9
  article-title: Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats
  publication-title: Neurochemistry Research
  doi: 10.1007/s11064-006-9040-z
– ident: ref23
– volume: 358
  start-page: 453
  year: 2008
  ident: ref4
  article-title: Mild traumatic brain injury in U.S. Soldiers returning from Iraq
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa072972
– volume: 64
  start-page: S174
  year: 2008
  ident: ref32
  article-title: Tympanic membrane perforation and hearing loss from blast overpressure in Operation Enduring Freedom and Operation Iraqi Freedom wounded
  publication-title: J Trauma
  doi: 10.1097/TA.0b013e318160773e
– volume: 971
  start-page: 1
  year: 2003
  ident: ref8
  article-title: N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia
  publication-title: Brain Research
  doi: 10.1016/S0006-8993(03)02244-3
– volume: 76
  start-page: 111
  year: 2009
  ident: ref2
  article-title: Blast-related mild traumatic brain injury: mechanisms of injury and impact on clinical care
  publication-title: Mt Sinai J Med
  doi: 10.1002/msj.20098
– reference: 18234757 - N Engl J Med. 2008 Jan 31;358(5):525-7
– reference: 7829942 - J Laryngol Otol. 1994 Nov;108(11):925-9
– reference: 19146459 - J Neurotrauma. 2008 Dec;25(12):1397-406
– reference: 21576092 - Arch Clin Neuropsychol. 2011 Jun;26(4):314-21
– reference: 20018732 - Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22468-73
– reference: 2161310 - Control Clin Trials. 1990 Apr;11(2):116-28
– reference: 12691831 - Brain Res. 2003 May 2;971(1):1-8
– reference: 17243171 - J Neurosci Res. 2007 Mar;85(4):805-15
– reference: 14744205 - Phys Ther. 2004 Feb;84(2):151-8
– reference: 15051148 - Neuroscience. 2004;125(1):91-101
– reference: 19136971 - Nat Neurosci. 2009 Feb;12(2):182-9
– reference: 17184943 - Hear Res. 2007 Apr;226(1-2):114-25
– reference: 11720806 - Pathophysiology. 2001 Dec;8(2):105-111
– reference: 15114624 - J Neurosci Res. 2004 May 15;76(4):519-27
– reference: 16758355 - Neurochem Res. 2006 Apr;31(4):473-81
– reference: 12965057 - J Neurotrauma. 2003 Aug;20(8):787-94
– reference: 15010086 - Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
– reference: 10903958 - Br J Pharmacol. 2000 Jul;130(6):1219-26
– reference: 18075949 - J Rehabil Res Dev. 2007;44(7):921-8
– reference: 14529474 - Curr Med Chem. 2003 Dec;10(23):2599-610
– reference: 9436612 - Free Radic Biol Med. 1998 Jan 1;24(1):39-48
– reference: 21946269 - Exp Neurol. 2011 Dec;232(2):280-9
– reference: 19158592 - J Head Trauma Rehabil. 2009 Jan-Feb;24(1):14-23
– reference: 17712668 - Acta Otolaryngol. 2007 Sep;127(9):914-9
– reference: 8442424 - Acta Otolaryngol. 1993 Jan;113(1):62-7
– reference: 14588937 - Arch Clin Neuropsychol. 1996;11(4):329-38
– reference: 18234750 - N Engl J Med. 2008 Jan 31;358(5):453-63
– reference: 21892121 - Otol Neurotol. 2011 Oct;32(8):1309-11
– reference: 20009782 - Otol Neurotol. 2010 Feb;31(2):232-6
– reference: 12037143 - Pharmacol Rev. 2002 Jun;54(2):271-84
– reference: 17691685 - Mil Med. 2007 Jul;172(7):726-30
– reference: 23093165 - JAMA. 2012 Oct 24;308(16):1676-84
– reference: 18292216 - Phys Ther. 2008 May;88(5):640-51
– reference: 9228664 - Pharmacol Rev. 1997 Jun;49(2):143-55
– reference: 19306373 - Mt Sinai J Med. 2009 Apr;76(2):111-8
– reference: 18376162 - J Trauma. 2008 Feb;64(2 Suppl):S174-8; discussion S178
– reference: 19903142 - Curr Med Chem. 2009;16(35):4668-78
– reference: 12225658 - J Neurotrauma. 2002 Aug;19(8):985-91
SSID ssj0053866
Score 2.498789
Snippet Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work...
Background Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little...
Background Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e54163
SubjectTerms Acetylcysteine
Acetylcysteine - pharmacology
Acetylcysteine - therapeutic use
Active control
Adolescent
Adult
American soldiers
Analysis
Auditory defects
Biology
Blast Injuries - drug therapy
Blast Injuries - physiopathology
Blood-brain barrier
Brain
Brain injuries
Brain Injuries - drug therapy
Brain Injuries - physiopathology
Brain research
Cognition
Cognition Disorders - prevention & control
Complications
Consciousness
Countermeasures
Cysteine
Cystine
Double-Blind Method
Double-blind studies
Eardrum
Explosions
Exposure
Female
Free Radical Scavengers - pharmacology
Free Radical Scavengers - therapeutic use
Head injuries
Headache
Hearing loss
Humans
Injuries
Iraq War, 2003-2011
Male
Medical diagnosis
Medicine
Memory Disorders - prevention & control
Military Personnel
Military technology
Neuropsychological Tests
Neurosciences
Noise
Ordnance
Otolaryngology
Otology
Placebos
Regression analysis
Science Policy
Secondary analysis
Severity of Illness Index
Side effects
Sleep
Sleep disorders
Sleep Initiation and Maintenance Disorders - prevention & control
Social and Behavioral Sciences
Surgery
Thiols
Trauma
Traumatic brain injury
War
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyqsLBQxCAiTSbmzHcbgtiKpwKBJQ1FvkV8qiNFmxyaF_gV_NjOONGlSpHDhuZta7OzMef6Mdf0PIC-kdRAUvEqmkS4RlVWJUoRKnJJw_ECFi6LY4lkcn4tNpdnpp1Bf2hA30wIPhDhjTi0xDHlVOihTWWVSFkM6bPLNM5wEawTG2LaaGHAy7WMp4UY7n6UH0y_66bfw-opRU8slBFPj6x6w8W9ft5irI-Xfn5KWj6PA2uRUxJF0O332H3PDNHbITd-mGvopU0q_vkt_Lc1-vopdpW1Ft-87T0D9da49PDMDnjkJlDj529HxVOwqf2QcmV2pwgAQIf4Llqbmgx4m2vruoqUUCaACob6mmru1N7RMDgNW9oaHJy7Q09sDXsGigsL1HTg4_fHt_lMTpC4mVsO9hPVNYz5Rnli9spqyGakcziwz8NkudcfAC6pnKAyYwVSoB2GjGiwpiAssQfp_MGrD3LqGGZZW2VcqdgOozr5TgmjkACiJVWqpiTvjWFaWN1OQ4IaMuw_9tOZQog2VLdGAZHTgnyfiu9UDNcY3-O_TyqIvE2uEBhFsZw628Ltzm5CnGSDncUh3TQ7nEK7sCJ7fPyfOggeQaDXbvnOl-syk_fv7-D0pfv0yUXkalqgVzWB1vTMBvQtKuiebeRBNShJ2IdzGit1bZgI1YnheFCO_cRvnV4mejGBfFjrzGtz3oIG0Sy0W2mJMHw6YYLcs4iKQCST7ZLhPTTyXN6kfgNgf4y6EIefg_fPWI3GRheEmaML5HZt2v3j8GCNmZJyFb_AHlIW_q
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvPCCGF_rGGAQEiDhrbETx-EFpRVjIDEQY2hvkWM7oygkZWkf-i_wV3OXuIGgCXhs7hI19-XfOec7Qh5LZ8EqRMKkkpaFhhcsV4liVklYf8BCwq7a4kgenoRvT6NTv-HW-LLKTUxsA7WtDe6R70PWFMdJAnj-5eI7w6lR-HXVj9C4TK4EHCwJT4ofvN5EYvBlKf1xOREH-147e4u6cnuIVQIpBstR27W_j82jRVk3FwHPP-snf1uQDq6Tax5J0rRT_Ra55KobZMv7akOf-obSz26SH-k3V869rmld0NSslo4eYxV1qR1emQKIXlKc42Gcpe_mpaWwiq3afq50imMkgPgV5E_zNT1iqXHLdUln2AYaYOoLmlJA4nnp2BRgq31OP-DufF7TWVcJX8JDsWJxfYucHLz6NDtkfgYDMxK8n2mTJ8Zx5bgRExMpoyHn0dxgH34TBTa38AOymsIBMsiLQAK80VwkBVgGJiPiNhlVIO9tQnMeFdoUgbAh5KBxoUKhuQW4EAZKS5WMidioIjO-QTnOySiz9qtbDIlKJ9kMFZh5BY4J6-9adA06_sE_RS33vNheu71Qn59l3lszzvUk0rB4KyvDAIx3UiShtC6PI8N1rMfkAdpI1p1V7YNEluLB3RDnt4_Jo5YDW2xUWMNzpldNk715__k_mI4_DpieeKaiBnEY7c9NwDth664B5-6AEwKFGZC30aI3UmmyXy4Fd26s_GLyw56MD8W6vMrVK-DB5kk8DqPJmNzpnKKXLBdAkgoo8cBdBqIfUqr5l7bDOYBgAanIzt__1l1ylbfDSQLGxS4ZLc9X7h5AxGV-v40DPwGvm2XX
  priority: 102
  providerName: ProQuest
Title Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study
URI https://www.ncbi.nlm.nih.gov/pubmed/23372680
https://www.proquest.com/docview/1327799495
https://www.proquest.com/docview/1283727450
https://pubmed.ncbi.nlm.nih.gov/PMC3553161
https://doaj.org/article/22a05a8018d641b890f946deb75c2a7a
http://dx.doi.org/10.1371/journal.pone.0054163
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: HH5
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVAFT
  databaseName: Colorado Digital library
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: KQ8
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Colorado Digital library
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: KQ8
  dateStart: 20061001
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: DOA
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: ABDBF
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: DIK
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: GX1
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M~E
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: RPM
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 7X7
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: BENPR
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Technology Collection
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 8FG
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/technologycollection1
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (ProQuest)
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 8C1
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M48
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELe27oUXxPi3jlEMQgIkXDVO4jhICKXVykBamTaK-hY5jjOKQlKaVqJfgU_NXZJGBBWNl0jNnS31fOf7XXy-I-S5MDFohe0zIUXMHM0TFklfslgK8D-gIU6VbTERZ1Pn48yd7ZFtz9ZagMXO0A77SU2Xaf_nj807MPi3ZdcGz9oO6i_yzPQRgwDG2CcH4Js46vm505wrgHWXp5eIWpjgA7u-TPevWVrOqqzp3-zcnUWaF7tg6d_ZlX-4q_EdcrvGmTSoFOOQ7JnsLjmsLbmgL-ty06_ukV_Bd5POa02geUIDvV4ZeoU51qky-GYIEHtFscuHNjE9n6cxBR-3Lqu90iE2mQDiN1gdGm3ohAXarDYpHWGRaACxb2hAAadHqWFDALXxa3qB3-6jnI6qPPkUJsV8xs19Mh2ffh6dsbpDA9MC9gamdORrw6Xh2h5oV2oFEZHiGqv0a9eKoxh-QMyTGMANUWIJAD-K234CeoOhiv2AdDKQ9xGhEXcTpRPLjh2IUL1EOrbiMYAJx5JKSL9L7O1ShLouX45dNNKwPJPzIIypJBviAob1AnYJa0YtqvIdN_APcZUbXiy-Xb7Il9dhbcsh52rgKnDtMhaOBao9SHxHxCbyXM2Vp7rkCepIWN1kbbaQMMBrvQ52d--SZyUHFuDIMMPnWq2LIvzw6ct_MF1dtphe1ExJDuLQqr5VAf8JC3u1OE9anLCN6Bb5CDV6K5UCZMQ9z_edcuRWy3eTnzZknBSz9jKTr4EHSytxz3EHXfKwMopGstwGkpBA8Vrm0hJ9m5LNv5b1zwEi2xCoHN8o5kfkFi-7l1iM2yeks1quzWPAkKuoR_a9mQdPObLwOX7fIwfD08nFZa_8KtMrt43fPvlzug
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9NADD-N8gAviPFvhcEOBAIksjV3ySVBQigtTC3bCmIb6lu43F1GUUjK0gr1K_Bh-IzYSRoImoCXPTZ2osb22T_nfDYhD4XRYBU8sIQvtOUollixH_iW9gXEH7AQp6q2GIvhsfNm4k7WyI_VWRgsq1z5xNJR61zhN_IdyJo8LwgAz7-cfbVwahTurq5GaFRmsWeW3yBlK16MXoF-HzG2-_poMLTqqQKWEmDPllRxoAzzDVO8p1xfSUDxkinsLK9cW8cafgBOTwzEujixBQRsyXiQwLsivObw3AvkosN7Dvbq9yZNgge-Q4j6eB737J3aGrZneWa2ERvZgrfCXzkloIkFnVmaF2cB3T_rNX8LgLtXyZUaudKwMrV1smaya2S99g0FfVI3sH56nXwPv5h0WtsWzRMaqsXc0EOs2k6lwSt9AO1zinNDlNH0YJpqClFzUfaPpX0cWwHEz6BvGi_p2AqVmS9TOsC20wCLn9OQAvKPU2P1ASbrZ_Qd7gbEOR1UlfcpPBQrJJc3yPG5aOcm6WQg7w1CY-YmUiU21w7kvF7iO1wyDfDEsX0p_KBL-EoVkaobouNcjjQqd_k8SIwqyUaowKhWYJdYzV2zqiHIP_j7qOWGF9t5lxfy05Oo9g4RY7LnSgALvhaODYullwSO0Cb2XMWkJ7tkC20kqs7GNk4pCvGgsIPz4rvkQcmBLT0yrBk6kYuiiEZvP_wH0-H7FtPjminJQRxK1uc04J2wVViLc7PFCY5JtcgbaNErqRTRryUMd66s_Gzy_YaMD8U6wMzkC-DBZk3Mc9xel9yqFkUjWcaBJHygeK3l0hJ9m5JNP5Ud1QF0c0h9bv_9b22RS8Ojg_1ofzTeu0Mus3Iwim0xvkk689OFuQvwdB7fK30CJR_P2wn9BBj5ovM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGkRAviPFvhcEMAgESWRs7cRIkhNqOamNQpo2hvgXHdkZRSMraCvUr8JH4dNwlbiBoAl722Nwlau7Od7-Lz3eEPBRGg1XwyBGh0I6nWOokYRQ6OhQQf8BCvKraYiR2j73XY3-8Rn6szsJgWeXKJ5aOWhcKv5F3IGsKgigCPN9JbVnEwc7w5fSrgxOkcKd1NU6jMpF9s_wG6dvsxd4O6PoRY8NX7we7jp0w4CgBtu1IlUTKsNAwxbvKD5UERC-Zwi7zynd1ouEHYPbUQNxLUldA8JaMRym8N0JtDs-9QC4G3ONYThaM62QP_IgQ9qgeD9yOtYztaZGbbcRJruCNUFhODKjjQmuaFbOzQO-ftZu_BcPhVXLFoljaq8xunayZ_BpZt35iRp_YZtZPr5PvvS8mm1g7o0VKe2oxN_QIK7gzafBKHwD8nOIMEWU0fTvJNIUIuih7ydI-jrAA4mfQPU2WdOT0lJkvMzrAFtQAkZ_THoUsIMmM0wfIrJ_RA9wZSAo6qKrwM3goVksub5Djc9HOTdLKQd4bhCbMT6VKXa49yH-DNPS4ZBqgiueGUoRRm_CVKmJlm6PjjI4sLnf8AkiSKsnGqMDYKrBNnPquadUc5B_8fdRyzYutvcsLxelJbD1FzJjs-hKAQ6iF58LC6aaRJ7RJAl8xGcg22UIbiatzsrWDint4aNjD2fFt8qDkwPYeOS6UE7mYzeK9dx_-g-nosMH02DKlBYhDSXtmA94J24Y1ODcbnOCkVIO8gRa9ksos_rWc4c6VlZ9Nvl-T8aFYE5ibYgE82LiJBZ7fbZNb1aKoJcs4kEQIlKCxXBqib1LyyaeyuzoAcA5p0O2__60tcgncT_xmb7R_h1xm5YwU12F8k7TmpwtzF5DqPLlXugRKPp63D_oJ28SnLg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amelioration+of+Acute+Sequelae+of+Blast+Induced+Mild+Traumatic+Brain+Injury+by+N-Acetyl+Cysteine%3A+A+Double-Blind%2C+Placebo+Controlled+Study&rft.jtitle=PloS+one&rft.au=Tsao%2C+Jack+W&rft.au=Hoffer%2C+Michael+E&rft.au=Balaban%2C+Carey&rft.au=Hoffer%2C+Barry&rft.date=2013-01-23&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=8&rft.issue=1&rft.spage=e54163&rft_id=info:doi/10.1371%2Fjournal.pone.0054163&rft.externalDBID=n%2Fa&rft.externalDocID=A478148795
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon